A share price of Aadi Bioscience Inc [AADI] is currently trading at $2.43, up 26.82%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The AADI shares have gain 22.98% over the last week, with a monthly amount glided 38.35%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 1, March 2024, Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO® for the Treatment of Malignant PEComa. In a post published today on Yahoo Finance, After 3 years of follow-up in AMPECT trial, confirmed clinically meaningful overall response rate, including multiple patients with complete responses.
From an analyst’s perspective:
Aadi Bioscience Inc [NASDAQ: AADI] stock has seen the most recent analyst activity on December 15, 2023, when H.C. Wainwright downgraded its rating to a Neutral. Previously, Jefferies started tracking the stock with Buy rating on January 11, 2022, and set its price target to $45. On October 01, 2021, Cowen initiated with a Outperform rating. Ladenburg Thalmann started tracking the stock assigning a Buy rating and suggested a price target of $51 on September 14, 2021. Piper Sandler initiated its recommendation with a Overweight and recommended $45 as its price target on September 08, 2021.
Aadi Bioscience Inc experienced fluctuations in its stock price throughout the past year between $1.55 and $10.92. Aadi Bioscience Inc [NASDAQ: AADI] shares were valued at $2.43 at the most recent close of the market.
Analyzing the AADI fundamentals
Trailing Twelve Months sales for Aadi Bioscience Inc [NASDAQ:AADI] were 23.25M which represents 40.38% growth. Gross Profit Margin for this corporation currently stands at 0.91% with Operating Profit Margin at -3.0%, Pretax Profit Margin comes in at -2.73%, and Net Profit Margin reading is -2.66%. To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is -0.45 and Total Capital is -0.58. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.0800 points at the first support level, and at 1.7200 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.6300, and for the 2nd resistance point, it is at 2.8300.
Aadi Bioscience Inc [AADI] reported earnings per share of -$0.6 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.72/share, meaning a difference of $0.12 and a surprise factor of 16.70%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.67 per share as compared to estimates of -$0.62 per share, a difference of -$0.05 representing a surprise of -8.10%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Aadi Bioscience Inc [NASDAQ:AADI] is 6.48. Also, the Quick Ratio is 6.30, while the Cash Ratio stands at 3.35. Considering the valuation of this stock, the price to sales ratio is 2.57, the price to book ratio is 0.51.
Transactions by insiders
Recent insider trading involved Desai Neil, EXECUTIVE CHAIRMAN, that happened on Mar 04 when 14964.0 shares were sold. EXECUTIVE CHAIRMAN, Desai Neil completed a deal on Mar 01 to sell 27036.0 shares. Meanwhile, Executive Chairman Desai Neil sold 42000.0 shares on Feb 01.
